[go: up one dir, main page]

WO2009013545A3 - Composés chimiques - Google Patents

Composés chimiques Download PDF

Info

Publication number
WO2009013545A3
WO2009013545A3 PCT/GB2008/050617 GB2008050617W WO2009013545A3 WO 2009013545 A3 WO2009013545 A3 WO 2009013545A3 GB 2008050617 W GB2008050617 W GB 2008050617W WO 2009013545 A3 WO2009013545 A3 WO 2009013545A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemical compounds
methods
compounds
treatmentfor
cancer
Prior art date
Application number
PCT/GB2008/050617
Other languages
English (en)
Other versions
WO2009013545A2 (fr
Inventor
Stephanos Ioannidis
Michelle Lamb
Mei Su
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Stephanos Ioannidis
Michelle Lamb
Mei Su
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Stephanos Ioannidis, Michelle Lamb, Mei Su filed Critical Astrazeneca Ab
Publication of WO2009013545A2 publication Critical patent/WO2009013545A2/fr
Publication of WO2009013545A3 publication Critical patent/WO2009013545A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte à des composés de formule (I) et à leurs sels, à des compositions pharmaceutiques, à leurs procédés d'utilisation et à leurs procédés de préparation. Ces composés sont utilisés dans le traitement du syndrome myéloprolifératif et du cancer.
PCT/GB2008/050617 2007-07-26 2008-07-23 Composés chimiques WO2009013545A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95222207P 2007-07-26 2007-07-26
US60/952,222 2007-07-26

Publications (2)

Publication Number Publication Date
WO2009013545A2 WO2009013545A2 (fr) 2009-01-29
WO2009013545A3 true WO2009013545A3 (fr) 2009-07-02

Family

ID=40281894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050617 WO2009013545A2 (fr) 2007-07-26 2008-07-23 Composés chimiques

Country Status (1)

Country Link
WO (1) WO2009013545A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5647998B2 (ja) 2009-03-13 2015-01-07 カトリーケ ユニバーシテイト ルーヴェン、ケー．ユー． ルーヴェン アール アンド ディー 免疫抑制剤としてのチアゾロピリミジン調節因子
RU2554874C2 (ru) 2010-01-14 2015-06-27 Санофи 2,5-замещенные производные оксазолопиримидина
KR101483215B1 (ko) * 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2012030894A1 (fr) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation Composés thiénopyridines et thiénopyrimidines et leurs procédés d'utilisation
IN2014DN07224A (fr) 2012-02-03 2015-04-24 Basf Se
EA201491667A1 (ru) 2012-03-13 2015-03-31 Басф Се Фунгицидные соединения пиримидина
CN103242341B (zh) * 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
EP3046915A1 (fr) 2013-09-16 2016-07-27 Basf Se Composés pyrimidines fongicides
WO2015036059A1 (fr) 2013-09-16 2015-03-19 Basf Se Composés fongicides de pyrimidine
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
CN110573518A (zh) 2017-01-26 2019-12-13 尤拉·S·赞特里佐斯 被取代的双环嘧啶基化合物及其组合物和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050065A2 (fr) * 2000-12-21 2002-06-27 Vertex Pharmaceuticals Incorporated Composes de pyrazole presentant une grande utilite comme inhibiteurs de proteine kinase
WO2005049033A1 (fr) * 2003-11-17 2005-06-02 Astrazeneca Ab Derives de pyrazole en tant qu'inhibiteurs de recepteur tyrosine kinases
WO2006123113A2 (fr) * 2005-05-16 2006-11-23 Astrazeneca Ab Composes chimiques
WO2007049041A1 (fr) * 2005-10-28 2007-05-03 Astrazeneca Ab Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu’inhibiteurs de tyrosine kinases dans le cadre d’un traitement anticancereux

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050065A2 (fr) * 2000-12-21 2002-06-27 Vertex Pharmaceuticals Incorporated Composes de pyrazole presentant une grande utilite comme inhibiteurs de proteine kinase
WO2005049033A1 (fr) * 2003-11-17 2005-06-02 Astrazeneca Ab Derives de pyrazole en tant qu'inhibiteurs de recepteur tyrosine kinases
WO2006123113A2 (fr) * 2005-05-16 2006-11-23 Astrazeneca Ab Composes chimiques
WO2007049041A1 (fr) * 2005-10-28 2007-05-03 Astrazeneca Ab Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu’inhibiteurs de tyrosine kinases dans le cadre d’un traitement anticancereux

Also Published As

Publication number Publication date
WO2009013545A2 (fr) 2009-01-29

Similar Documents

Publication Publication Date Title
WO2009016410A3 (fr) Composés chimiques 831
WO2009013545A3 (fr) Composés chimiques
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
WO2012019426A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
PT2150530E (pt) Derivados de sulfonamida substituídos
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
WO2012019430A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
WO2008145688A3 (fr) Nouveaux composés
WO2008013838A3 (fr) Dérivés de pyridizinone
WO2011058027A3 (fr) Composés de purine n-9-substitués, compositions et procédés d'utilisation
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
WO2009156462A3 (fr) Composés organiques
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2010150211A3 (fr) Utilisation de dérivés d'indoles dans le traitement du cancer
MY147890A (en) 9-(pyrazol-3-yl)-9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidaz0 [4,5-b] pyridin-5-amine derivatives and their use for the treatment of cancer
WO2013004995A8 (fr) Composés pyrimidinones et leur utilisation
WO2010129918A8 (fr) Promédicaments à base de triptolide
WO2010089327A3 (fr) Dérivés d'indole en tant qu'agents anti-cancéreux
WO2009025785A3 (fr) Ligands de récepteur cb2 pour le traitement de la douleur
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
WO2013040227A3 (fr) Composés thérapeutiques
TW200738627A (en) Trialkylsilyl-indoles
WO2008131946A3 (fr) Dérivés d'amide substitués
WO2010121675A3 (fr) Thiazolyl-benzimidazoles
WO2008116663A3 (fr) Dérivés de tétrahydro-naphtalène-amine substitués par un hétérocyclyle, leur préparation et utilisation en tant que médicaments

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788592

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08788592

Country of ref document: EP

Kind code of ref document: A2